Patent intelligence · US
US 11623930
Imidazodiazepinediones and methods of use thereof
Imidazodiazepinediones and methods of use thereof
Patent details — US 11623930
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2023
- Expiration
- Apr 6, 2043
- Applicant
- Goldfinch Bio, Inc.
- Claims
- 10
- CPC classes
- A61P, A61P13/12, A61P25/00, A61P35/00
Quick answer
US 11623930 (Imidazodiazepinediones and methods of use thereof) is held by Goldfinch Bio, Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Goldfinch Bio, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61P, A61P13/12, A61P25/00, A61P35/00
More from Goldfinch Bio, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12390496
Methods for treating ulcerative colitis
granted -
US 12350298
Microbiome related immunotherapies
granted -
US 12290538
Methods and products for treatment of gastrointestinal disorders
granted -
US 12285447
Methods and compositions for treating ulcerative colitis
granted -
US 12161678
Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
granted -
US 12005086
Microbiome related immunotherapies
granted -
US 11911419
Compositions and methods for treating epilepsy and related disorders
granted -
US 11890308
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
granted
Frequently asked questions
What is US patent 11623930?
US 11623930 (Imidazodiazepinediones and methods of use thereof) is held by Goldfinch Bio, Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11623930?
Goldfinch Bio, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 33 pharmaceutical patents for this assignee.
When does US 11623930 expire?
Our index shows an expiration date of Apr 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.